Citations (74)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (12)
Robert Amato & Mika Stepankiw. (2013) Evaluation of everolimus in renal cell cancer. Expert Opinion on Pharmacotherapy 14:9, pages 1229-1240.
Read now
Read now
Putao Cen & Robert J Amato. (2012) Treatment of advanced pancreatic neuroendocrine tumors: potential role of everolimus. OncoTargets and Therapy 5, pages 217-224.
Read now
Read now
David Neal Franz. (2011) Everolimus: an mTOR inhibitor for the treatment of tuberous sclerosis. Expert Review of Anticancer Therapy 11:8, pages 1181-1192.
Read now
Read now
Robert Amato. (2011) Everolimus for the treatment of advanced renal cell carcinoma. Expert Opinion on Pharmacotherapy 12:7, pages 1143-1155.
Read now
Read now
Angela M Liu, Michelle Z Xu, Jinfei Chen, Ronnie T Poon & John M Luk. (2010) Targeting YAP and Hippo signaling pathway in liver cancer. Expert Opinion on Therapeutic Targets 14:8, pages 855-868.
Read now
Read now
Gerhard Treiber. (2009) mTOR inhibitors for hepatocellular cancer: a forward-moving target. Expert Review of Anticancer Therapy 9:2, pages 247-261.
Read now
Read now
Olivia Aranha & Mark Agulnik. (2008) Molecularly targeted therapies in adult soft tissue sarcomas: present approach and future directions. Expert Opinion on Therapeutic Targets 12:2, pages 197-207.
Read now
Read now
Angiolo Gadducci, Roberta Tana, Stefania Cosio, Antonio Fanucchi & Andrea Riccardo Genazzani. (2008) Molecular target therapies in endometrial cancer: From the basic research to the clinic. Gynecological Endocrinology 24:5, pages 239-249.
Read now
Read now
Hanne Hagland, Julie Nikolaisen, Linn I Hodneland, Bjøorn T Gjertsen, Øystein Bruserud & Karl J Tronstad. (2007) Targeting mitochondria in the treatment of human cancer: a coordinated attack against cancer cell energy metabolism and signalling. Expert Opinion on Therapeutic Targets 11:8, pages 1055-1069.
Read now
Read now
Angiolo Gadducci, Stefania Cosio & Andrea Riccardo Genazzani. (2007) Novel targeted therapies in epithelial ovarian cancer: from basic research to the clinic. Expert Review of Endocrinology & Metabolism 2:2, pages 225-238.
Read now
Read now
Luis Fayad & Anas Younes. (2006) Novel treatment strategies for aggressive non-Hodgkin’s lymphoma. Expert Opinion on Pharmacotherapy 7:6, pages 733-748.
Read now
Read now
Georgios V Georgakis & Anas Younes. (2006) From Rapa Nui to rapamycin: targeting PI3K/Akt/mTOR for cancer therapy. Expert Review of Anticancer Therapy 6:1, pages 131-140.
Read now
Read now
Articles from other publishers (62)
Deng-Yu Tseng, Sz-Tsan Wang, Rolissa Ballantyne & Chun-Hung Liu. (2023) Adenosine 5′-monophosphate-activated protein kinase (AMPK) negatively regulates the immunity and resistance to Vibrio alginolyticus of white shrimp, Penaeus vannamei. Fish & Shellfish Immunology 139, pages 108884.
Crossref
Crossref
Brice Moukengue, Morgane Lallier, Louise Marchandet, Marc Baud’huin, Franck Verrecchia, Benjamin Ory & Francois Lamoureux. (2022) Origin and Therapies of Osteosarcoma. Cancers 14:14, pages 3503.
Crossref
Crossref
Suchetana Mukherjee & Dwaipayan Sinha. 2022. Coronavirus Drug Discovery. Coronavirus Drug Discovery
101
135
.
Mona Sadeghalvad & Nima Rezaei. 2022. Encyclopedia of Infection and Immunity. Encyclopedia of Infection and Immunity
481
493
.
Qi Wang, Mengqi Luo, Bo Xiang, Siyuan Chen & Yi Ji. (2020) The efficacy and safety of pharmacological treatments for lymphangioleiomyomatosis. Respiratory Research 21:1.
Crossref
Crossref
Yoshikazu Kuwahara, Mehryar Habibi Roudkenar, Yusuke Urushihara, Yohei Saito, Kazuo Tomita, Amaneh Mohammadi Roushandeh, Tomoaki Sato, Akihiro Kurimasa & Manabu Fukumoto. (2017) Clinically relevant radioresistant cell line: a simple model to understand cancer radioresistance. Medical Molecular Morphology 50:4, pages 195-204.
Crossref
Crossref
Yanyong Wang, Qinying Ma, Xiaowei Ma, Zhongxia Zhang, Na Liu & Mingwei Wang. (2017) Role of mammalian target of rapamycin signaling in autophagy and the neurodegenerative process using a senescence accelerated mouse-prone 8 model. Experimental and Therapeutic Medicine 14:2, pages 1051-1057.
Crossref
Crossref
Jeanne C. Larson, Sara D. Allstadt, Timothy M. Fan, Chand Khanna, Paul J. Lunghofer, Ryan J. Hansen, Daniel L. Gustafson, Alfred M. Legendre, Gina D. Galyon, Amy K. LeBlanc & Tomas Martin-Jimenez. (2016) Pharmacokinetics of orally administered low-dose rapamycin in healthy dogs. American Journal of Veterinary Research 77:1, pages 65-71.
Crossref
Crossref
Hilary J. Goldberg, Sergio Harari, Vincent Cottin, Ivan O. Rosas, Elizabeth Peters, Shibadas Biswal, Yi Cheng, Sanjeev Khindri, John M. Kovarik, Shenglin Ma, Francis X. McCormack & Elizabeth Petri Henske. (2015) Everolimus for the treatment of lymphangioleiomyomatosis: a phase II study. European Respiratory Journal 46:3, pages 783-794.
Crossref
Crossref
Meir Bialer, Svein I. Johannessen, René H. Levy, Emilio Perucca, Torbjörn Tomson & H. Steve White. (2015) Progress report on new antiepileptic drugs: A summary of the Twelfth Eilat Conference (EILAT XII). Epilepsy Research 111, pages 85-141.
Crossref
Crossref
Sounak Gupta & Donna E. Hansel. 2015. Urological Oncology. Urological Oncology
563
590
.
Saami Khalifian, Giorgio Raimondi, WP Andrew Lee & Gerald Brandacher. (2014) Taming inflammation by targeting cytokine signaling: new perspectives in the induction of transplantation tolerance. Immunotherapy 6:5, pages 637-653.
Crossref
Crossref
Mariella Gruber Filbin, Sukriti K Dabral, Maria F Pazyra-Murphy, Shakti Ramkissoon, Andrew L Kung, Ekaterina Pak, Jarom Chung, Matthew A Theisen, Yanping Sun, Yoko Franchetti, Yu Sun, David S Shulman, Navid Redjal, Barbara Tabak, Rameen Beroukhim, Qi Wang, Jean Zhao, Marion Dorsch, Silvia Buonamici, Keith L Ligon, Joseph F Kelleher & Rosalind A Segal. (2013) Coordinate activation of Shh and PI3K signaling in PTEN-deficient glioblastoma: new therapeutic opportunities. Nature Medicine 19:11, pages 1518-1523.
Crossref
Crossref
Emma Puighermanal, Arnau Busquets-Garcia, Maria Gomis-González, Giovanni Marsicano, Rafael Maldonado & Andrés Ozaita. (2013) Dissociation of the Pharmacological Effects of THC by mTOR Blockade. Neuropsychopharmacology 38:7, pages 1334-1343.
Crossref
Crossref
Zaira Leni, Geetha Parakkal & Alexandre Arcaro. (2013) Emerging Metabolic Targets in the Therapy of Hematological Malignancies. BioMed Research International 2013, pages 1-12.
Crossref
Crossref
Olasunkanmi A.J. AdegokeAbdikarim AbdullahiPegah Tavajohi-Fini. (2012) mTORC1 and the regulation of skeletal muscle anabolism and mass. Applied Physiology, Nutrition, and Metabolism 37:3, pages 395-406.
Crossref
Crossref
Sant P. ChawlaArthur P. StaddonLaurence H. BakerScott M. SchuetzeAnthony W. TolcherGina Z. D'AmatoJean-Yves BlayMonica M. MitaKamalesh K. SankhalaLori BerkVictor M. RiveraTim ClacksonJohn W. LoewyFrank G. HaluskaGeorge D. Demetri. (2012) Phase II Study of the Mammalian Target of Rapamycin Inhibitor Ridaforolimus in Patients With Advanced Bone and Soft Tissue Sarcomas. Journal of Clinical Oncology 30:1, pages 78-84.
Crossref
Crossref
Victor M. Rivera, Rachel M. Squillace, David Miller, Lori Berk, Scott D. Wardwell, Yaoyu Ning, Roy Pollock, Narayana I. Narasimhan, John D. Iuliucci, Frank Wang & Tim Clackson. (2011) Ridaforolimus (AP23573; MK-8669), a Potent mTOR Inhibitor, Has Broad Antitumor Activity and Can Be Optimally Administered Using Intermittent Dosing Regimens. Molecular Cancer Therapeutics 10:6, pages 1059-1071.
Crossref
Crossref
Sana Zargar, Tracy S. Moreira, Helena Samimi-Seisan, Senthure Jeganathan, Dhanshri Kakade, Nushaba Islam, Jonathan Campbell & Olasunkanmi A. J. Adegoke. (2011) Skeletal muscle protein synthesis and the abundance of the mRNA translation initiation repressor PDCD4 are inversely regulated by fasting and refeeding in rats. American Journal of Physiology-Endocrinology and Metabolism 300:6, pages E986-E992.
Crossref
Crossref
Lauren J. Akers, Wendy Fang, Alejandro G. Levy, Anna R. Franklin, Peng Huang & Patrick A. Zweidler-McKay. (2011) Targeting glycolysis in leukemia: A novel inhibitor 3-BrOP in combination with rapamycin. Leukemia Research 35:6, pages 814-820.
Crossref
Crossref
Ki-Hwan Eum & Michael Lee. (2011) Targeting the autophagy pathway using ectopic expression of Beclin 1 in combination with rapamycin in drug-resistant v-Ha-ras-transformed NIH 3T3 cells. Molecules and Cells 31:3, pages 231-238.
Crossref
Crossref
Cheryl Clark, Oleksandr Ekshyyan & Cherie-Ann O. Nathan. 2011. Signaling Pathways in Squamous Cancer. Signaling Pathways in Squamous Cancer
383
405
.
P. Schöffski, P. Reichardt, J.-Y. Blay, H. Dumez, J.A. Morgan, I. Ray-Coquard, N. Hollaender, A. Jappe & G.D. Demetri. (2010) A phase I–II study of everolimus (RAD001) in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors. Annals of Oncology 21:10, pages 1990-1998.
Crossref
Crossref
Jie Zheng, Alice Hudder, Kim Zukowski & Raymond F. Novak. (2010) Rapamycin sensitizes Akt inhibition in malignant human breast epithelial cells. Cancer Letters 296:1, pages 74-87.
Crossref
Crossref
Robert T. Abraham, James J. Gibbons & Edmund I. Graziani. 2010.
329
366
.
James J. Gibbons, Robert T. Abraham & Ker Yu. (2009) Mammalian Target of Rapamycin: Discovery of Rapamycin Reveals a Signaling Pathway Important for Normal and Cancer Cell Growth. Seminars in Oncology 36, pages S3-S17.
Crossref
Crossref
A. Cataneo-Dávila, J. Zúñiga-Varga, R. Correa-Rotter & J. Alberú. (2009) Renal Function Outcomes in Kidney Transplant Recipients After Conversion to Everolimus-Based Immunosuppression Regimen with CNI Reduction or Elimination. Transplantation Proceedings 41:10, pages 4138-4146.
Crossref
Crossref
J.-C. Soria, F.A. Shepherd, J.-Y. Douillard, J. Wolf, G. Giaccone, L. Crino, F. Cappuzzo, S. Sharma, S.H. Gross, S. Dimitrijevic, L. Di Scala, H. Gardner, L. Nogova & V. Papadimitrakopoulou. (2009) Efficacy of everolimus (RAD001) in patients with advanced NSCLC previously treated with chemotherapy alone or with chemotherapy and EGFR inhibitors. Annals of Oncology 20:10, pages 1674-1681.
Crossref
Crossref
Eric Klann. (2009) Thwarting Dyskinesia by Targeting mTORC1. Science Signaling 2:80.
Crossref
Crossref
Emanuela SantiniMyriam HeimanPaul GreengardEmmanuel ValjentGilberto Fisone. (2009)
Inhibition of mTOR Signaling in Parkinson’s Disease Prevents
l
-DOPA–Induced Dyskinesia
. Science Signaling 2:80.
Crossref
Crossref
S. Priyadarshini Narayanan, Ana I. Flores, Feng Wang & Wendy B. Macklin. (2009) Akt Signals through the Mammalian Target of Rapamycin Pathway to Regulate CNS Myelination. The Journal of Neuroscience 29:21, pages 6860-6870.
Crossref
Crossref
Maurice A. M. van Steensel, Michel van Geel, Sadhanna Badeloe, Pamela Poblete-Gutiérrez & Jorge Frank. (2009) Molecular pathways involved in hair follicle tumor formation: all about mammalian target of rapamycin?. Experimental Dermatology 18:2, pages 185-191.
Crossref
Crossref
Girieca Lorusso & Curzio Rüegg. (2008) The tumor microenvironment and its contribution to tumor evolution toward metastasis. Histochemistry and Cell Biology 130:6, pages 1091-1103.
Crossref
Crossref
Anthony Calabro, Julia Tai, Steven L. Allen & Daniel R. Budman. (2008) In-vitro synergism of m-TOR inhibitors, statins, and classical chemotherapy: potential implications in acute leukemia. Anti-Cancer Drugs 19:7, pages 705-712.
Crossref
Crossref
Cristiana Sessa, Aymeric Guibal, Gianluca Del Conte & Curzio Rüegg. (2008) Biomarkers of angiogenesis for the development of antiangiogenic therapies in oncology: tools or decorations?. Nature Clinical Practice Oncology 5:7, pages 378-391.
Crossref
Crossref
Jorge A. Garcia & David Danielpour. (2008) Mammalian target of rapamycin inhibition as a therapeutic strategy in the management of urologic malignancies. Molecular Cancer Therapeutics 7:6, pages 1347-1354.
Crossref
Crossref
Josep Tabernero, Federico Rojo, Emiliano Calvo, Howard Burris, Ian Judson, Katharine Hazell, Erika Martinelli, Santiago Ramon y Cajal, Suzanne Jones, Laura Vidal, Nicholas Shand, Teresa Macarulla, Francisco Javier Ramos, Sasa Dimitrijevic, Ulrike Zoellner, Pui Tang, Michael Stumm, Heidi A. Lane, David Lebwohl & José Baselga. (2008) Dose- and Schedule-Dependent Inhibition of the Mammalian Target of Rapamycin Pathway With Everolimus: A Phase I Tumor Pharmacodynamic Study in Patients With Advanced Solid Tumors. Journal of Clinical Oncology 26:10, pages 1603-1610.
Crossref
Crossref
Elias Drakos, George Z. Rassidakis & L. Jeffrey Medeiros. (2008) Mammalian target of rapamycin (mTOR) pathway signalling in lymphomas. Expert Reviews in Molecular Medicine 10.
Crossref
Crossref
Rees L. Lee & Carl W. White. 2008. Pediatric Respiratory Medicine. Pediatric Respiratory Medicine
1031
1038
.
Amanda Wedgwood & Anas Younes. 2008. Targeted Cancer Therapy. Targeted Cancer Therapy
157
182
.
Elisabeth I. Heath & Michael A. Carducci. 2008. Prostate Cancer. Prostate Cancer
383
400
.
Elisabeth I. Heath & Michael A. Carducci. 2008. Molecular Targeting in Oncology. Molecular Targeting in Oncology
263
290
.
Tobin Strom, Manuel Haschke, Jared Boyd, Mark Roberts, Lili Arabshahi, Peter Marbach & Uwe Christians. (2007) Crossreactivity of Isolated Everolimus Metabolites With the Innofluor Certican Immunoassay for Therapeutic Drug Monitoring of Everolimus. Therapeutic Drug Monitoring 29:6, pages 743-749.
Crossref
Crossref
Tobin Strom, Manuel Haschke, Yan Ling Zhang, Jamie Bendrick-Peart, Jared Boyd, Mark Roberts, Lili Arabshahi, Peter Marbach & Uwe Christians. (2007) Identification of Everolimus Metabolite Patterns in Trough Blood Samples of Kidney Transplant Patients. Therapeutic Drug Monitoring 29:5, pages 592-599.
Crossref
Crossref
Luisella Righi, Marco Volante, Ida Rapa, Giorgio V. Scagliotti & Mauro Papotti. (2007) Neuro-endocrine tumours of the lung. A review of relevant pathological and molecular data. Virchows Archiv 451:S1, pages 51-59.
Crossref
Crossref
Diana Behrens, Anne E. Lykkesfeldt & Iduna Fichtner. (2007) The mTOR pathway inhibitor RAD001 (everolimus) is highly efficacious in tamoxifen-sensitive and -resistant breast cancer xenografts. Targeted Oncology 2:3, pages 135-144.
Crossref
Crossref
Cherie-Ann O. Nathan, Nazanin Amirghahari, Xiaohua Rong, Tony Giordano, Don Sibley, Mary Nordberg, Jonathan Glass, Anshul Agarwal & Gloria Caldito. (2007) Mammalian Target of Rapamycin Inhibitors as Possible Adjuvant Therapy for Microscopic Residual Disease in Head and Neck Squamous Cell Cancer. Cancer Research 67:5, pages 2160-2168.
Crossref
Crossref
Sherry A. Weppler, Mechthild Krause, Agnieszka Zyromska, Philippe Lambin, Michael Baumann & Bradly G. Wouters. (2007) Response of U87 glioma xenografts treated with concurrent rapamycin and fractionated radiotherapy: Possible role for thrombosis. Radiotherapy and Oncology 82:1, pages 96-104.
Crossref
Crossref
Carlos Garcia-Echeverria. 2007. Cancer. Cancer
169
206
.
Anirban P. Mitra, Ram H. Datar & Richard J. Cote. (2006) Molecular Pathways in Invasive Bladder Cancer: New Insights Into Mechanisms, Progression, and Target Identification. Journal of Clinical Oncology 24:35, pages 5552-5564.
Crossref
Crossref
Nicola Tolliday, Paul A. Clemons, Paul Ferraiolo, Angela N. Koehler, Timothy A. Lewis, Xiaohua Li, Stuart L. Schreiber, Daniela S. Gerhard & Scott Eliasof. (2006) Small Molecules, Big Players: the National Cancer Institute's Initiative for Chemical Genetics. Cancer Research 66:18, pages 8935-8942.
Crossref
Crossref
Celeste L. Kremer, Rob R. Klein, Jenny Mendelson, Walden Browne, Linda K. Samadzedeh, Kristie Vanpatten, Lindsey Highstrom, Gary A. Pestano & Raymond B. Nagle. (2006) Expression of mTOR signaling pathway markers in prostate cancer progression. The Prostate 66:11, pages 1203-1212.
Crossref
Crossref
Luke A. J. O'Neill. (2006) Targeting signal transduction as a strategy to treat inflammatory diseases. Nature Reviews Drug Discovery 5:7, pages 549-563.
Crossref
Crossref
Ron Waksman, Rajbabu Pakala, Richard Baffour, David Hellinga, Rufus Seabron, Frank Kolodgie & Renu Virmani. (2006) Optimal dosing and duration of oral everolimus to inhibit in-stent neointimal growth in rabbit iliac arteries. Cardiovascular Revascularization Medicine 7:3, pages 179-184.
Crossref
Crossref
Andrew J. Carter, Anastasia Brodeur, Robin Collingwood, Sarah Ross, Lori Gibson, Chi‐An Wang, Scott Haller, Leslie Coleman & Renu Virmani. (2006) Experimental efficacy of an everolimus eluting cobalt chromium stent. Catheterization and Cardiovascular Interventions 68:1, pages 97-103.
Crossref
Crossref
Angiolo Gadducci, Stefania Cosio & Andrea Riccardo Genazzani. (2006) Old and new perspectives in the pharmacological treatment of advanced or recurrent endometrial cancer: Hormonal therapy, chemotherapy and molecularly targeted therapies. Critical Reviews in Oncology/Hematology 58:3, pages 242-256.
Crossref
Crossref
Chand KhannaLee J. Helman. (2006) Molecular Approaches in Pediatric Oncology. Annual Review of Medicine 57:1, pages 83-97.
Crossref
Crossref
Stephan Wullschleger, Robbie Loewith & Michael N. Hall. (2006) TOR Signaling in Growth and Metabolism. Cell 124:3, pages 471-484.
Crossref
Crossref
Nancy E. Hynes & Anne Boulay. (2006) The mTOR Pathway in Breast Cancer. Journal of Mammary Gland Biology and Neoplasia 11:1, pages 53-61.
Crossref
Crossref
Mika A. Sovak & David R. Spriggs. 2006. Cancer Drug Resistance. Cancer Drug Resistance
543
557
.
R-H Xu, H Pelicano, H Zhang, F J Giles, M J Keating & P Huang. (2005) Synergistic effect of targeting mTOR by rapamycin and depleting ATP by inhibition of glycolysis in lymphoma and leukemia cells. Leukemia 19:12, pages 2153-2158.
Crossref
Crossref
Gary V. Borzillo. (2005) Akt and emerging models for tumor cell energetics. Drug Discovery Today: Therapeutic Strategies 2:4, pages 331-336.
Crossref
Crossref